• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » All About...Menopause

All About...Menopause

September 1, 2004
Daniel Carlat, MD
From The Carlat Psychiatry Report
Issue Links: Editorial Information | PDF of Issue
Daniel Carlat, MD Dr. Carlat has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.
Over the last few years, the concept of menopause has hit the national radar screen with a vengeance. One of the reasons for the onslaught of publicity was a nasty bit of research news released in 2002, when the initial results of the Women's Health Initiative Study were made public (JAMA. 2002; 288:321-333).

The study showed that hormone replacement therapy (HRT) is much more dangerous than anybody realized. Prempro, which is a combination of estrogen (0.625 mg) and progesterone (2.5 mg), was associated with an increased risk for heart attacks, strokes, blood clots, and breast cancer. This news dealt a huge blow to estrogen. Prescriptions of Prempro and other HRT treatments plummeted from 91 million in 2001 to 57 million in 2003, and they have surely decreased even more by now (JAMA 2004; 291:47-53).

How is all this affecting our psychiatric practices? Well, if your practice is anything like mine, you have been seeing an influx of estrogen refugees--peri- and post-menopausal women who had felt great on HRT, discontinued the treatment because of the bad press, and now are suffering insomnia, hot flashes, and all around dysphoria. What can we offer such women?

First, a quick lesson in menopause. Occurring at an average age of 51, it is typically defined as the cessation of menstruation for 12 consecutive months. Perimenopause (also termed "menopausal transition") is defined as the few years leading up to menopause, during which periods become irregular and various menopausal symptoms emerge, such as hot flashes. The perimenopause lasts 4-5 years on average.

What is happening biologically is that as the ovaries age, they become less and less responsive to gonadotrophic hormones such as FSH, and therefore produce less and less estrogen. Without sufficient estrogen, there can be no thickening of the uterine lining, and hence, no menstrual bleeding. Low estrogen also causes hot flashes and night sweats, followed by later symptoms such as vaginal dryness and thinning, bladder problems, and dryness of the hair and skin. In addition, low estrogen leads to several major health risks, including an increased risk of osteoporosis, cardiovascular disease, and possibly even Alzheimer's dementia (see Am J Psychiatry 1997; 154:1641-1647 for a review of some of this data).

A frequent question from patients transitioning to menopause is, "Am I at greater risk to develop a major depression?" The answer is, "Possibly." Studies that survey groups of women referred to menopause clinics report high rates of depressive disorders (nearly 30% in one study--see Arch Gen Psychiatry 2001; 58:306), but such clinics may attract a more severely affected group of women. A recent study showed that depressive symptoms appear to increase during the perimenopause, are especially common in women with hot flashes, and then decrease in prevalence after menopause (Arch Gen Psychiatry 2004;61:62-70).

What works for perimenopausal depression? Estrogen, for one, especially when given as the transdermal 17ßestradiol patch (100 μg QD), as reported in a successful placebo-controlled trial (Arch Gen Psychiatry. 2001; 58:529- 534). Yes, many physicians still prescribe estrogen, notwithstanding recent research findings, but this depends on a complicated assessment of risks vs. benefits for a particular patient (JAMA 2004; 291:1621-1625). These days, it is the rare psychiatrist who feels up to this task, and most of us would be wise to ask the neighborhood OB/GYN to take care of any estrogen prescriptions.

Not surprisingly, SSRIs also appear to work for perimenopausal depression. A recent uncontrolled study reported 90% remission rates when Celexa (20- 60 mg QD) was either added to the estradiol patch or used as monotherapy (J Clin Psychiatry 2003; 64: 473-479).

In addition to depressive symptoms, your patients will likely ask you for help with specific symptoms of menopause, especially hot flashes. While estrogen is the gold standard treatment, typically reducing hot flash frequency and severity by 80%, both SSRIs and Effexor have been proven helpful, causing a 60% improvement in clinical trials (see JAMA 2003; 289:2827-34 for the data on Paxil CR).

Finally, if you are inclined toward natural medications, try black cohosh, shown effective for the treatment of hot flashes and mild depressive symptoms in controlled trials (Ann Intern Med 2002; 137:805-813).

TCR VERDICT:
Menopause symptoms: Try SSRIs, SNRIs, and black cohosh.
General Psychiatry
Carlat 150x150
Daniel Carlat, MD

20 Years of The Carlat Report

More from this author
www.thecarlatreport.com
Issue Date: September 1, 2004
SUBSCRIBE NOW
Table Of Contents
Premenstrual Syndrome: What’s in a Name?
Dr. Adele Viguera On Peripartum Mood Disorders
All About...Menopause
SSRIs and Pregnancy: Troubling Questions Remain
PMDD: What It Is, How To Help
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto84222831.jpg
    General Psychiatry

    The Adderall Shortage

    Adderall is in short supply, and the backlog is having a domino effect on other stimulants. Find out why, and how long it will last.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.